JP2023523218A5 - - Google Patents
Info
- Publication number
- JP2023523218A5 JP2023523218A5 JP2022563971A JP2022563971A JP2023523218A5 JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5 JP 2022563971 A JP2022563971 A JP 2022563971A JP 2022563971 A JP2022563971 A JP 2022563971A JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- weeks
- storage
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013801P | 2020-04-22 | 2020-04-22 | |
| US63/013,801 | 2020-04-22 | ||
| PCT/IB2021/053254 WO2021214658A1 (en) | 2020-04-22 | 2021-04-20 | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523218A JP2023523218A (ja) | 2023-06-02 |
| JP2023523218A5 true JP2023523218A5 (enExample) | 2024-04-30 |
| JP7876454B2 JP7876454B2 (ja) | 2026-06-19 |
Family
ID=75639945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563971A Active JP7876454B2 (ja) | 2020-04-22 | 2021-04-20 | ヘテロ二量体ヒトインターロイキン－１５（ｈｅｔＩＬ－１５）の医薬組成物及び医薬製品 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210330747A1 (enExample) |
| EP (1) | EP4138782A1 (enExample) |
| JP (1) | JP7876454B2 (enExample) |
| KR (1) | KR20230004655A (enExample) |
| CN (1) | CN115443127A (enExample) |
| AR (1) | AR122428A1 (enExample) |
| AU (1) | AU2021260989A1 (enExample) |
| BR (1) | BR112022020973A2 (enExample) |
| CA (1) | CA3178895A1 (enExample) |
| CO (1) | CO2022014867A2 (enExample) |
| IL (1) | IL297326A (enExample) |
| MX (1) | MX2022013352A (enExample) |
| TW (1) | TW202214290A (enExample) |
| WO (1) | WO2021214658A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114080412B (zh) | 2019-06-28 | 2023-08-25 | 国立大学法人东京大学 | 蛋白质内包高分子胶束 |
| JP2024540570A (ja) * | 2021-11-18 | 2024-10-31 | 山▲東▼先声生物制▲薬▼有限公司 | Ｉｌ－１５突然変異体融合タンパク質医薬組成物 |
| WO2024173571A1 (en) * | 2023-02-14 | 2024-08-22 | Amcyte Pharma, Inc. | Interleukin formulations for in vivo use |
| CN117883565A (zh) * | 2023-12-25 | 2024-04-16 | 中山大学 | 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用 |
| WO2025206413A1 (en) * | 2024-03-28 | 2025-10-02 | The University Of Tokyo | Protein-enclosing polymeric complexes |
| WO2026126081A1 (en) * | 2024-12-11 | 2026-06-18 | Kashiv Biosciences, Llc | A stable pharmaceutical composition of fusion protein |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| WO2007001677A2 (en) | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| SG2013054218A (en) * | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| CA2727953C (en) | 2008-08-22 | 2017-05-16 | Magna Seating Inc. | Disc recliner with reduced backlash |
| EP3366337B1 (en) * | 2009-10-21 | 2019-12-04 | Owen Mumford Limited | Autoinjector |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| EP3578200A1 (en) * | 2013-02-22 | 2019-12-11 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| US10335460B2 (en) * | 2014-07-29 | 2019-07-02 | Novartis Ag | IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions |
| US20190117690A1 (en) * | 2016-04-06 | 2019-04-25 | The University State Of America As Represented By The Secretary Of The Department Of Health And Hum | Use of heterodimeric il-15 in adoptive cell transfer |
| US11273205B2 (en) * | 2017-07-25 | 2022-03-15 | Jiangsu Hengrui Medicine Co., Ltd. | IL-15 protein complex pharmaceutical composition |
| CN121086085A (zh) * | 2018-06-22 | 2025-12-09 | 科优基因公司 | 新型白介素-15 (il-15)融合蛋白及其用途 |
| JP2022530130A (ja) * | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
-
2021
- 2021-04-20 AU AU2021260989A patent/AU2021260989A1/en active Pending
- 2021-04-20 MX MX2022013352A patent/MX2022013352A/es unknown
- 2021-04-20 TW TW110114219A patent/TW202214290A/zh unknown
- 2021-04-20 EP EP21720852.9A patent/EP4138782A1/en active Pending
- 2021-04-20 CA CA3178895A patent/CA3178895A1/en active Pending
- 2021-04-20 CN CN202180030326.7A patent/CN115443127A/zh active Pending
- 2021-04-20 JP JP2022563971A patent/JP7876454B2/ja active Active
- 2021-04-20 BR BR112022020973A patent/BR112022020973A2/pt unknown
- 2021-04-20 WO PCT/IB2021/053254 patent/WO2021214658A1/en not_active Ceased
- 2021-04-20 KR KR1020227040050A patent/KR20230004655A/ko active Pending
- 2021-04-20 IL IL297326A patent/IL297326A/en unknown
- 2021-04-20 US US17/234,914 patent/US20210330747A1/en not_active Abandoned
- 2021-04-22 AR ARP210101082A patent/AR122428A1/es unknown
-
2022
- 2022-10-19 CO CONC2022/0014867A patent/CO2022014867A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102864931B1 (ko) | 인간화 항-전립선 특이적 막 항원(psma) 항체 약물 접합체 | |
| ES2706428T3 (es) | Inmunoconjugado de IL-12 | |
| CN111328346B (zh) | 基于人铁蛋白和蛋白酶可切割肽的融合蛋白及其作为化学治疗载体的用途 | |
| ES2633453T3 (es) | Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos | |
| ES3031307T3 (en) | Proteins binding nkg2d, cd16 and egfr | |
| ES2774296T3 (es) | Terapias de combinación para tratar cánceres quimiorresistentes | |
| JP2005508981A5 (enExample) | ||
| JP2010047601A (ja) | カハラリドｆ | |
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| KR20230010221A (ko) | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 | |
| US20110124564A1 (en) | Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same | |
| JP7660523B2 (ja) | アルカリリン酸塩に基づいた癌治療 | |
| JP2020509737A5 (enExample) | ||
| CN103347514B (zh) | Fgfr1胞外域组合疗法 | |
| TW201907947A (zh) | 一種ｉｌ－１５蛋白質複合物醫藥組成物及其用途 | |
| ES2674491T3 (es) | Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos | |
| JP2004512370A5 (enExample) | ||
| ES2930351T3 (es) | Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante | |
| WO2024153224A1 (zh) | 一种含艾日布林衍生物药物偶联物的药物组合物 | |
| EP3996680B1 (en) | Stable formulations of recombinant proteins | |
| JP2023553562A (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 | |
| CN116710114A (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| AU2015216941B2 (en) | Polypeptide fragments of 168A-T2 and compositions comprising them for use in treating cancer | |
| JP2023512337A (ja) | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 | |
| WO2024179453A1 (zh) | 重组人源化抗Nectin-4单抗-MMAE偶联药物的药物组合物 |